EMA Recommends Approval of Datroway for First-Line Treatment of Triple-Negative Breast Cancer
AstraZeneca and Daiichi Sankyo have received a positive recommendation from the European Medicines Agency's CHMP for Datroway as a first-line treatment for unresectable or metastatic triple-negative breast cancer in patients who are not eligible for immunotherapy, supported by Phase 3 trial results demonstrating improved survival and disease control.
Metastatic Breast Cancer Treatment | 29/06/2026 | By News Bureau
Atossa Therapeutics Receives FDA Go-Ahead for (Z)-Endoxifen IND in Metastatic Breast Cancer
Atossa Therapeutics announced that it has received a “Study May Proceed” letter from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for (Z)-endoxifen in metastatic breast cancer, clearing the way for the initiation of clinical studies evaluating the therapy.
Metastatic Breast Cancer Treatment | 07/01/2026 | By News Bureau | 274
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy